| (Values in U.S. Thousands) | Mar, 2026 | Mar, 2026 | Mar, 2026 | Mar, 2026 | Mar, 2026 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 0 | 0 | 0 | 0 | 0 |
| Net Income Growth | unch | unch | unch | unch | unch |
China Pediatric Pharms (CPDU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
China Pediatric Pharmaceuticals, Inc. was incorporated in the State of Nevada on April 20, 2005, under the name "Belford Enterprises B.C. Ltd." On October 9, 2009, the Company's name was changed to "China Pediatric Pharmaceuticals, Inc". On September 30, 2009, the Company acquired control of Shaanxi Jiali Pharmaceutical Co., Ltd., a children's pharmaceuticals manufacturer in China, by way of the Company's acquisition of China Children Pharmaceutical, Inc., a Company organized under the laws of Hong Kong. The name change was effected through a parent/subsidiary merger of its wholly-owned subsidiary, China Pediatric Pharmaceuticals, Inc., with and into the Company, with the Company as the surviving Corporation. To effectuate the merger, the Company filed its Articles of Merger with the Nevada Secretary of State and the merger became effective on October 9, 2009. Through its operating entity, Shaanxi Jiali, it is profitable, mid-sized Chinese pharmaceutical Company that identifies, discovers, develops manufactures and distributes both prescription and over-the counter drugs (including conventional and Traditional Chinese Medicines ("TCMs")) mainly for the treatment of some of the most common children's ailments and diseases. Approximately 72% of its products are planned for children's use and approximately 28% for adult use. Its operating Company, Shaanxi Jiali, has its own manufacturing facility located in Baoji, Shaanxi Province. In the fiscal year ended December 31, 2009, its revenues were mainly derived from sales of 26 products listed below, of which 7 products are Western medicines and 19 are ready-made Chinese traditional medicines. The Company currently has 26 products that are manufactured by both its in-house production facility and through OEM companies. Of these products, 13 are produced in-house at its production plant. It currently markets products under three brands: Cooers Brand Products, Qingsongling Brand Products and Zianzhi Brand Product. Shaanxi Jiali currently holds nine registered trade names for the following medicine names: Image, Sanseqi, Cooer, Tailaishi, Qingsongling, Beishiting, Zhiben, Xianzhi, Chugan, Yunlaitongjingbao and has filed trademark applications, the approvals of which are pending, for 3 other medicine names or general trademarks. Shaanxi Jiali competes with other companies, many of whom are developing or could be expected to develop products similar to Shaanxi Jiali.